Atorvastatin has been found to inhibit the activation of the NOD-like receptor family, NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome pathway induced by cholesterol crystals, thereby reducing the expression of pro-inflammatory cytokines interleukin (IL)-1β and IL-18, which are implicated in NAFLD progression [85]. Here, IL18 is linked to metabolic dysfunction-associated steatotic liver disease.